Literature DB >> 15165029

Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells.

Jeannene Butler1, Diana Lana, Oliver Round, Kenneth LaMontagne.   

Abstract

Sphingosine 1-phosphate (S1P) is a pleiotropic lysophospholipid mediator involved in many cellular responses, including transient calcium mobilization, activation of MAP kinase signaling, inhibition of adenylyl cyclase and increased cell migration. S1P has been shown to be an effective activator of vascular endothelial cells via the interaction with cell surface G protein-coupled receptors (GPCRs), namely S1P-R (formerly EDG-R). The potent immunomodulator, FTY720, is phosphorylated by sphingosine kinase (SK) to FTY720-P. Recently it was shown that FTY720-P, not FTY720, can bind to four out of five of the S1P-R. In the present study, we evaluated the effects of FTY720, FTY720-P, and analogues of FTY720-P: an active (R)-enantiomer [AFD(R)] and an inactive (S)-enantiomer [AFD(S)], on endothelial cell functions. Treatment of HUVEC with FTY720-P, but not FTY720, lead to a robust transient increase in calcium mobilization, detected using the fluorometric imaging plate reader (FLIPR) assay. Additionally, only the phosphorylated derivative (FTY720-P) stimulated MAPK activation. We also observed complementary activities of S1P and FTY720-P in an established in vitro endothelial morphogenesis (Matrigel tube formation) assay and an in vitro endothelial cell migration assay. Using a potent inhibitor of sphingosine kinase, N,N-dimethylsphingosine (DMS), FTY720's effects were inhibited in the migration assay, suggesting that FTY720-P is the active mediator. The effects of FTY720-P in these assays were inhibited by pre-treatment with PTx (pertussis toxin), indicating the requirement of a Gi-coupled S1P receptor. These findings suggest that agonist of S1P-R are able to regulate important endothelial cell properties, which may lead to a greater insight into vascular functions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15165029     DOI: 10.1016/j.prostaglandins.2003.11.003

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  10 in total

1.  Selective activation of sphingosine 1-phosphate receptors 1 and 3 promotes local microvascular network growth.

Authors:  Lauren S Sefcik; Caren E Petrie Aronin; Anthony O Awojoodu; Soo J Shin; Feilim Mac Gabhann; Timothy L MacDonald; Brian R Wamhoff; Kevin R Lynch; Shayn M Peirce; Edward A Botchwey
Journal:  Tissue Eng Part A       Date:  2010-11-09       Impact factor: 3.845

2.  Engineering vascularized tissues using natural and synthetic small molecules.

Authors:  Lauren S Sefcik; Caren E Petrie Aronin; Edward A Botchwey
Journal:  Organogenesis       Date:  2008-10       Impact factor: 2.500

3.  Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteins.

Authors:  Kimberly Romero Rosales; Gurpreet Singh; Kevin Wu; Jie Chen; Matthew R Janes; Michael B Lilly; Eigen R Peralta; Leah J Siskind; Michael J Bennett; David A Fruman; Aimee L Edinger
Journal:  Biochem J       Date:  2011-10-15       Impact factor: 3.857

4.  Vessel-specific role of sphingosine kinase 1 in the vasoconstriction of isolated basilar arteries.

Authors:  Salvatore Salomone; Guray Soydan; Peter Ching-Tze Ip; Kristen M Park Hopson; Christian Waeber
Journal:  Pharmacol Res       Date:  2010-09-17       Impact factor: 7.658

Review 5.  Pharmacological relevance and potential of sphingosine 1-phosphate in the vascular system.

Authors:  Mirjam Schuchardt; Markus Tölle; Jasmin Prüfer; Markus van der Giet
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

6.  FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  Paolo Neviani; Ramasamy Santhanam; Joshua J Oaks; Anna M Eiring; Mario Notari; Bradley W Blaser; Shujun Liu; Rossana Trotta; Natarajan Muthusamy; Carlo Gambacorti-Passerini; Brian J Druker; Jorge Cortes; Guido Marcucci; Ching-Shih Chen; Nicole M Verrills; Denis C Roy; Michael A Caligiuri; Clara D Bloomfield; John C Byrd; Danilo Perrotti
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

7.  Sphingosine-1-phosphate promotes lymphangiogenesis by stimulating S1P1/Gi/PLC/Ca2+ signaling pathways.

Authors:  Chang Min Yoon; Bok Sil Hong; Hyung Geun Moon; Seyoung Lim; Pann-Ghill Suh; Yoon-Keun Kim; Chi-Bom Chae; Yong Song Gho
Journal:  Blood       Date:  2008-06-09       Impact factor: 22.113

Review 8.  Cardiovascular effects of fingolimod: A review article.

Authors:  Mohaddeseh Behjati; Masoud Etemadifar; Morteza Abdar Esfahani
Journal:  Iran J Neurol       Date:  2014-07-04

Review 9.  Systematic review of the role of angiopoietin-1 and angiopoietin-2 in Plasmodium species infections: biomarkers or therapeutic targets?

Authors:  Gerdie M de Jong; Jasper J Slager; Annelies Verbon; Jaap J van Hellemond; Perry J J van Genderen
Journal:  Malar J       Date:  2016-12-01       Impact factor: 2.979

10.  Cenerimod, a novel selective S1P1 receptor modulator with unique signaling properties.

Authors:  Luca Piali; Magdalena Birker-Robaczewska; Cyrille Lescop; Sylvie Froidevaux; Nicole Schmitz; Keith Morrison; Christopher Kohl; Markus Rey; Rolf Studer; Enrico Vezzali; Patrick Hess; Martine Clozel; Beat Steiner; Martin H Bolli; Oliver Nayler
Journal:  Pharmacol Res Perspect       Date:  2017-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.